Clostridium Difficile Toxin A Antibody [CoraFluor™ 1] - (Research Grade actoxumab Biosimilar)

• Reactivity: Hu
• Applications: ELISA, Flow, Func
• Clonality: Monoclonal
• Host: Human
• Conjugate: CoraFluor 1

Clostridium Difficile Toxin A Antibody [CoraFluor™ 1] - (Research Grade actoxumab Biosimilar) Summary

• Description: CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Cdiff Toxin A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Human
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Functional
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark. Do not freeze.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein A purified

Notes

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

Alternate Names for Array

• TcdA
• ToxA
• Toxin A

Background

Clostridium difficile, or C. difficile, a gram positive anaerobic bacterium, is the major causative agent of colitis and diarrhoea that can occur following antibiotic intake. C. difficile infection is one of the most common hospital acquired infections. When C. difficile colonize the gut, they release two potent toxins, toxin A and toxin B, which bind to certain receptors in the lining of the colon and ultimately cause diarrhoea and inflammation of the large intestine.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for Clostridium Difficile Toxin A Antibody (NBP3-28826CL1). (Showing 1 - 1 of 1 FAQ).

1. I am seeking monoclonal antibodies specific for the C Terminal binding regions of clostridum difficile toxins A and B (aa1852-2366)?
   • I would recommend catalog # NB100-62473. Although it is a polyclonal, it is the only one that we know binds to the C-Terminal portion of the protein. The other antibodies we have against both targets are synthesized from the full length sequence. We do not routinely epitope map our antibodies so we cannot be certain where they are binding. This polyclonal is synthesized against a small 10 amino acid region of the protein so it should be highly specific to that location.